New whitepaper: The dangers of blue light What is the best way to protect ourselves against damaging blue light? Our latest whitepaper focuses on the impact of blue light, on the young and old, and what can be done to…
What does a larger and more aged population mean for our approach to eye health? This is the question posed by the Nutraceutical Business Review, who recently published our paper on MPS II and macular screening. A condensed-version of our…
How well educated are your patients about the types of age-related macular degeneration? The symptoms of dry and wet AMD are similar but their prognosis can be very different, with wet developing much quicker and requiring treatment immediately. Dry can…
Low MP is a significant, modifiable risk factor for AMD, and once it is detected it requires management to preserve sight. Early detection is vital and putting the right processes in, backed up with the right equipment, will help improve…
What can we do to control the development of the fourth leading cause of blindness? Our latest whitepaper explores the affect our ageing population will have on cases of AMD, as well as other risk factors increasing incidence of the…